To exploit bacterialNOS for the development of new therapeutics, recognition of alternative NOS surfaces and pharmacophores suitable for drug binding is required.
2
These data provide the first evidence that bacterialNOS (bNOS) inhibitors can work synergistically with oxidative stress to enhance MRSA killing.
3
Development of potent and selective bacterialNOS inhibitors is complicated by the high active site sequence and structural conservation shared with the mammalian NOS isoforms.